How Do We Manage Antiaggregation in BARC I Bleeding after AMI?

Dual antiplatelet therapy (DAPT) after acute myocardial infarction (AMI) has been shown useful to reduce thrombotic events, but one of its downsides is bleeding, especially in elderly patients.

BARC bleeding type I, also called nuisance bleeding (NB), is of low frequency, but its evolution and impact remain unclear, as does its management. 

A subanalysis of the TALOS-AMI was carried out. This study included 2583 patients receiving DAPT after AMI with ASA and ticagrelor. 416 of these patients (16.1%) presented NB.

Patients presenting NB were younger (58 vs. 60 p=0.01) and showed no difference in comorbidities. Kidney function was conserved and there were no differences as regards treated vessel or number of implanted stents. 

De-escalation was from ticagrelor to clopidogrel.

At one-year followup, NB was not associated to increased BARC bleeding 2, 3, or 5 (hazard ratio [HR]‚ 1.29 [95% CI‚ 0.7–2.14]) or major cardiovascular events (HR, 1.94 [95% CI, 1.08–3.48]; P=0.026).

Read also: Valve-in-Valve Shows Good Evolution after 2 Years.

De-escalation from ticagrelor to clopidogrel reduced the incidence of bleeding compared against ticagrelor plus ASA in bleeding type I (HR‚ 0.31 [95% CI‚ 0.10–0.92]).

There was no increase in cardiovascular events at de-escalation. 

Conclusion

Nuisance bleeding (BARC type I) is frequent after AMI the first month after DAPT with ticagrelor and was associated to early bleeding. De-escalation after NB might reduce bleeding events with no increase in ischemic events. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Miembro del Consejo Editorial de SOLACI.org.

Original Title: Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.

Reference: Eun Ho Choo,e tal. Circ Cardiovasc Interv. 2022;15:e012157. DOI: 10.1161/CIRCINTERVENTIONS.122.012157.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...